Gano Babban Bincike
Tsufan zuciya na iya haifar da raguwa kaɗan a wani sinadari da ake kira NAD⁺. Wani sabon binciken bera da aka wallafa a Cardiovascular Research (Huang et al.) ya nuna cewa farfado da NAD⁺ na iya kawar da ƙwayoyin zuciya masu tsufa (senescent) kuma ya inganta yadda zuciyar da ta tsufa ke nutsuwa tsakanin bugun jini. Sai dai fa’idar ta bayyana ne kawai a cikin berayen maza, kuma sinadarin da ya fi tasiri ga muhimman enzayim na tsawon rai ba shi ne sanannen kari ba.
Menene Ya Faru a Zuciyar Berayen Maza Masu Tsufa
Masana sun kwatanta berayen ƙanana da manya daga jinsin maza da mata. A cikin manyan berayen maza, matakin NAD⁺ a zuciya ya ragu. Bisa ga takardar, abubuwa uku ne suka ba da gudummawa:
- Rashin haɓaka sinadarin – ƙirƙirar NAD⁺ ya ragu ƙasa da yadda ya kamata.
- Ƙuntata motsi na mitochondria – saboda haka ba a samu isasshen NAD⁺ a wuraren da ake buƙata ba.
- Ƙaruwa a cinye sinadarin – an ƙara amfani da NAD⁺ sosai.
Da ragowar NAD⁺, aikin enzayim biyu masu alaƙa da tsawon rai, SIRT1 da SIRT6, ya ragu. Ƙwayoyin zuciya da suka daina rabuwa (senescent cardiomyocytes) sun taru, kuma zuciya ta nuna alamu na diastolic dysfunction, myocardial hypertrophy, da fibrosis.
Kamar yadda marubutan suka nuna, senescence na cardiomyocytes alama ce ta tsufan zuciya kuma tana da alaka kai tsaye da rashin nutsuwa da kuma ƙarfi ga cutar zuciya a tsofaffi.
Binciken Sinadaran: NR vs. NRH
Kungiyar ta gwada sinadarai biyu da ake kira precursors na NAD⁺:
- Nicotinamide riboside (NR) – sanannen sinadari da ake samu a ƙarin abinci.
- Dihydronicotinamide riboside (NRH) – wani nau’i da aka rage na NR, wanda ba a saba ji ba.
A cikin sel na zuciya da aka dasa a dakin gwaje‑gwaje, raguwar NAD⁺ ta haifar da senescence. Cika da NR ko NRH duka ya mayar da al’amari zuwa daidaito.
A cikin berayen maza masu tsufa, watanni biyu na maganin NR ko NRH ya:
- Rage alamar senescence.
- Inganta aikin diastolic.
- Rage girman zuciya da kuma fibrosis.
Dalilin Da Ya Sa NRH Ya Fi Fice
Duk sinadarai biyun suna ƙara aikin SIRT1 kuma suna rage alamar dakatar da zagayowar sel. Amma NRH ya samar da ƙarin ƙarfi wajen kunna SIRT1. Bisa ga marubuta, wannan ƙarfafa SIRT1 yana kawar da acetyl a kan SIRT6, wanda ke ba SIRT6 damar haɗa da histones kuma ya ƙara gyaran DNA.
Kammalawar takardar tana cewa cika NAD⁺, musamman ta amfani da NRH, na iya juyar da matsalolin zuciya da suka danganci senescence ta hanyar haɗa aikin SIRT1 da SIRT6. Takardar ba ta ce NRH ya ba da sauyi fiye da NR ba; kawai ta nuna ƙwarewar SIRT1 mafi girma, don haka bambancin yana da mahimmanci.
Juyin Halitta: Mata Ba Su Amfana Ba
Berayen mata masu tsufa suma sun samu rashin nutsuwa na zuciya, amma matakin NAD⁺ a zuciyarsu ba ya raguwa sosai, kuma ba su amsa ga NR ko NRH ba.
Marubutan sun fassara hakan a matsayin alamar cewa hanyoyin tsufan zuciya suna bambanta tsakanin jinsi. A mata, ƙarancin NAD⁺ ba shi da alaka da matsalar, don haka cika tanki ba ya magance komai. Sun jaddada cewa dole ne a yi la’akari da jinsi a lokacin ƙirƙirar magungunan da suka danganci NAD⁺.
Abubuwan Da Za A Iya Yi (Tare da Gaskata Gaskiya)
Kun tambayi adadi, lokacin amfani, da wa ya dace. Ga abin da takardar ke tallafawa da inda ta tsaya.
Adadi: Takardar ba ta bayyana adadi ba, kuma ba za a iya juya adadin da aka yi a berayen zuwa takamaiman adadi ga mutane ba. Duk wani da ke ba da “adadin NR da ke kare zuciya” daga wannan bincike yana yin zato ne.
Lokaci: Maganin berayen ya ɗauki watanni biyu, an fara shi a dabbobi da suka riga sun tsufa. Wannan yana nuna cewa tasirin ba ya faruwa nan take; an samu sakamako ne bayan an riga an sami tsufa. Ba a bayar da bayanin mafi kyawun lokacin ɗauka ko tsawon lokacin da mutum zai ci gaba da amfani ba.
Waɗanda Zai Iya Amfana: Sakamakon na nuni da tsofaffin maza da ke da rashin nutsuwa ko alamu na tsufan zuciya. Wannan zato ne don gwaje‑gwajen gaba, ba shawara ta kai‑tsaye ba.
Waɗanda Ya Kamata Su Guji Hype:
- Duk wanda ke jiran tabbacin amfanin mutane. Takardar ba ta bayar da bayanan mutum ba.
- Matan da ke fatan samun irin wannan tasiri. A wannan bincike, berayen mata ba su amsa ba.
- Mutanen da ke da cutar zuciya da aka gano kuma suke tunanin maye gurbin magani da ƙari. Ku tattauna da likitan zuciya kafin ku fara wani abu.
- Duk wanda ke neman NRH a matsayin samfur. Takardar ba ta tabbatar da amincinsa ko samuwar sa ga mutane ba.
Abubuwan Da Har Ba Mu San Su Ba
- Shin NAD⁺ na raguwa a zuciyar mutane kamar yadda yake a berayen maza?
- Shin NRH zai yi aiki a mutane, kuma a wane adadi?
- Me ya sa mata ke riƙe NAD⁺ a zuciya amma har yanzu suna samun rashin nutsuwa?
- Shin fa’idodin za su ci gaba bayan dakatar da magani?
Babban Gaskiya
Wannan bincike ya nuna a fili cewa ƙarancin NAD⁺ yana haifar da senescence na cardiomyocytes a zuciyar berayen maza masu tsufa, kuma farfado da shi da NR, musamman NRH, na iya inganta aikin diastolic tare da rage girman zuciya da fibrosis. Sakamakon na nuna bambanci tsakanin jinsi, wanda ke gargadi game da tunanin cewa dabarun tsawon rai guda ɗaya na aiki ga kowa. A halin yanzu, wannan hanya ce mai ƙwarin gwiwa ga masu bincike fiye da tsarin ƙari na yau da kullum.
Source: Huang et al., "NAD+ replenishment reduces cardiomyocyte senescence and improves diastolic function in the aged male heart," Cardiovascular Research. DOI: 10.1093/cvr/cvag265. PubMed: https://pubmed.ncbi.nlm.nih.gov/42958931/
